Bioengineered non-coding RNA agent (BERA) in action

References

• Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15 Spec No 1:R17-29; PMID:16651366; http://dx.doi.org/10.1093/hmg/ddl046
   PubMed Web of Science ®Google Scholar
• Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 2003; 67:657-85; PMID:14665679; http://dx.doi.org/10.1128/MMBR.67.4.657-685.2003
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
   PubMed Web of Science ®Google Scholar
• Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18:1121-6; PMID:21633392; http://dx.doi.org/10.1038/gt.2011.79
   PubMed Web of Science ®Google Scholar
• Shah MY, Calin GA. MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA 2014; 5:537-48; PMID:24687772; http://dx.doi.org/10.1002/wrna.1229
   PubMed Web of Science ®Google Scholar
• Ho PY, Yu AM. Bioengineering of noncoding RNAs for research agents and therapeutics. Wiley Interdiscip Rev RNA 2016; 7:186-97; PMID:26763749; http://dx.doi.org/10.1002/wrna.1324
   PubMed Web of Science ®Google Scholar
• Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3:120; PMID:22783274; http://dx.doi.org/10.3389/fgene.2012.00120
   PubMedGoogle Scholar
• Adams D, Cauquil C, Theaudin M, Rousseau A, Algalarrondo V, Slama MS. Current and future treatment of amyloid neuropathies. Expert Rev Neurother 2014; 14:1437-51; PMID:25416603; http://dx.doi.org/10.1586/14737175.2014.983905
   PubMed Web of Science ®Google Scholar
• Beckert B, Masquida B. Synthesis of RNA by in vitro transcription. Methods Mol Biol 2011; 703:29-41; PMID:21125481; http://dx.doi.org/10.1007/978-1-59745-248-9_3
   PubMedGoogle Scholar
• Pranchevicius MC, Vieira TR. Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. Bioengineered 2013; 4:305-12; PMID:23644447; http://dx.doi.org/10.4161/bioe.24666
   PubMed Web of Science ®Google Scholar
• Balabanova L, Golotin V, Podvolotskaya A, Rasskazov V. Genetically modified proteins: functional improvement and chimeragenesis. Bioengineered 2015; 6:262-74; PMID:26211369; http://dx.doi.org/10.1080/21655979.2015.1075674
   PubMed Web of Science ®Google Scholar
• Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7:21-39; PMID:18097458; http://dx.doi.org/10.1038/nrd2399
   PubMed Web of Science ®Google Scholar
• Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci U S A 1979; 76:106-10; PMID:85300; http://dx.doi.org/10.1073/pnas.76.1.106
   PubMed Web of Science ®Google Scholar
• Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy. Drug Metab Dispos 2016; 44:308-19; PMID:26566807; http://dx.doi.org/10.1124/dmd.115.067470
   PubMed Web of Science ®Google Scholar
• Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK, Tang T. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 2014; 538:217-27; PMID:24406620; http://dx.doi.org/10.1016/j.gene.2013.12.019
   PubMed Web of Science ®Google Scholar
• Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011; 12:329-40; PMID:21499294; http://dx.doi.org/10.1038/nrg2968
   PubMed Web of Science ®Google Scholar
• Kubowicz P, Zelaszczyk D, Pekala E. RNAi in clinical studies. Curr Med Chem 2013; 20:1801-16; PMID:23432579; http://dx.doi.org/10.2174/09298673113209990118
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15:509-24; PMID:25027649; http://dx.doi.org/10.1038/nrm3838
   PubMed Web of Science ®Google Scholar
• Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015; 87:108-19; PMID:25666164; http://dx.doi.org/10.1016/j.addr.2015.01.007
   PubMed Web of Science ®Google Scholar
• Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70:7027-30; PMID:20807816; http://dx.doi.org/10.1158/0008-5472.CAN-10-2010
   PubMed Web of Science ®Google Scholar
• van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012; 110:496-507; PMID:22302756; http://dx.doi.org/10.1161/CIRCRESAHA.111.247916
   PubMed Web of Science ®Google Scholar
• Huang L, Jin J, Deighan P, Kiner E, McReynolds L, Lieberman J. Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol 2013; 31:350-6; PMID:23475073; http://dx.doi.org/10.1038/nbt.2537
   PubMed Web of Science ®Google Scholar
• Jin J, Cid M, Poole CB, McReynolds LA. Protein mediated miRNA detection and siRNA enrichment using p19. Biotechniques 2010; 48:xvii-xxiii; PMID:20569217; http://dx.doi.org/10.2144/000113364
   PubMed Web of Science ®Google Scholar
• Qiu W, Park JW, Scholthof HB. Tombusvirus P19-mediated suppression of virus-induced gene silencing is controlled by genetic and dosage features that influence pathogenicity. Mol Plant Microbe Interact 2002; 15:269-80; PMID:11952130; http://dx.doi.org/10.1094/MPMI.2002.15.3.269
   PubMed Web of Science ®Google Scholar
• Silhavy D, Molnar A, Lucioli A, Szittya G, Hornyik C, Tavazza M, Burgyán J. A viral protein suppresses RNA silencing and binds silencing-generated, 21- to 25-nucleotide double-stranded RNAs. EMBO J 2002; 21:3070-80; PMID:12065420; http://dx.doi.org/10.1093/emboj/cdf312
   PubMed Web of Science ®Google Scholar
• Pitulle C, Dsouza L, Fox GE. A low molecular weight artificial RNA of unique size with multiple probe target regions. Syst Appl Microbiol 1997; 20:133-6; PMID:11540055; http://dx.doi.org/10.1016/S0723-2020(97)80057-4
   PubMed Web of Science ®Google Scholar
• Pitulle C, Hedenstierna KO, Fox GE. A novel approach for monitoring genetically engineered microorganisms by using artificial, stable RNAs. Appl Environ Microbiol 1995; 61:3661-6; PMID:7487004
   PubMed Web of Science ®Google Scholar
• Pitulle C, Hedenstierna KO, Fox GE. Useful properties of restriction enzymes that recognize interrupted palindromes. Biotechniques 1996; 21:619-20, 22; PMID:8891210
   PubMed Web of Science ®Google Scholar
• Liu Y, Stepanov VG, Strych U, Willson RC, Jackson GW, Fox GE. DNAzyme-mediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in Escherichia coli. BMC Biotechnol 2010; 10:85; PMID:21134283; http://dx.doi.org/10.1186/1472-6750-10-85
   PubMed Web of Science ®Google Scholar
• Zhang X, Potty AS, Jackson GW, Stepanov V, Tang A, Liu Y, Kourentzi K, Strych U, Fox GE, Willson RC. Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. J Mol Recognit 2009; 22:154-61; PMID:19195013; http://dx.doi.org/10.1002/jmr.917
   PubMed Web of Science ®Google Scholar
• Stepanov VG, Fox GE. In vivo production of small recombinant RNAs embedded in a 5S rRNA-derived protective scaffold. Methods Mol Biol 2015; 1316:45-65; PMID:25967052; http://dx.doi.org/10.1007/978-1-4939-2730-2_5
   PubMedGoogle Scholar
• Ponchon L, Dardel F. Recombinant RNA technology: the tRNA scaffold. Nat Methods 2007; 4:571-6; PMID:17558412; http://dx.doi.org/10.1038/nmeth1058
   PubMed Web of Science ®Google Scholar
• Ponchon L, Beauvais G, Nonin-Lecomte S, Dardel F. A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc 2009; 4:947-59; PMID:19478810; http://dx.doi.org/10.1038/nprot.2009.67
   PubMed Web of Science ®Google Scholar
• Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. Chimeric MicroRNA-1291 biosynthesized efficiently in escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos 2015; 43:1129-36; PMID:25934574; http://dx.doi.org/10.1124/dmd.115.064493
   PubMedGoogle Scholar
• Li MM, Wang WP, Wu WJ, Huang M, Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos 2014; 42:1791-5; PMID:25161167; http://dx.doi.org/10.1124/dmd.114.060145
   PubMed Web of Science ®Google Scholar
• Nelissen FH, Leunissen EH, van de Laar L, Tessari M, Heus HA, Wijmenga SS. Fast production of homogeneous recombinant RNA–towards large-scale production of RNA. Nucleic Acids Res 2012; 40:e102; PMID:22457065; http://dx.doi.org/10.1093/nar/gks292
   PubMed Web of Science ®Google Scholar
• Paige JS, Nguyen-Duc T, Song W, Jaffrey SR. Fluorescence imaging of cellular metabolites with RNA. Science 2012; 335:1194; PMID:22403384; http://dx.doi.org/10.1126/science.1218298
   PubMed Web of Science ®Google Scholar
• Paige JS, Wu KY, Jaffrey SR. RNA mimics of green fluorescent protein. Science 2011; 333:642-6; PMID:21798953; http://dx.doi.org/10.1126/science.1207339
   PubMed Web of Science ®Google Scholar
• Ponchon L, Catala M, Seijo B, El Khouri M, Dardel F, Nonin-Lecomte S, Tisné C. Co-expression of RNA-protein complexes in Escherichia coli and applications to RNA biology. Nucleic Acids Res 2013; 41:e150; PMID:23804766; http://dx.doi.org/10.1093/nar/gkt576
   PubMed Web of Science ®Google Scholar
• Chen QX, Wang WP, Zeng S, Urayama S, Yu AM. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res 2015; 43:3857-69; PMID:25800741; http://dx.doi.org/10.1093/nar/gkv228
   PubMed Web of Science ®Google Scholar
• Pereira PA, Tomas JF, Queiroz JA, Figueiras AR, Sousa F. Recombinant pre-miR-29b for Alzheimer s disease therapeutics. Sci Rep 2016; 6:19946; PMID:26818210; http://dx.doi.org/10.1038/srep19946
   PubMed Web of Science ®Google Scholar
• Pereira P, Pedro AQ, Tomas J, Maia CJ, Queiroz JA, Figueiras A, Sousa F. Advances in time course extracellular production of human pre-miR-29b from Rhodovulum sulfidophilum. Appl Microbiol Biotechnol 2016; 100:3723-34; PMID:26860940; http://dx.doi.org/10.1007/s00253-016-7350-x
   PubMed Web of Science ®Google Scholar
• Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, et al. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization. J Pharmacol Exp Ther 2015; 354:131-41; PMID:26022002; http://dx.doi.org/10.1124/jpet.115.225631
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tu MJ, Yu YF, Wang WP, Chen QX, Qiu JX, Yu AX, Yu AM. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. Biochem Pharmacol 2015; 98:602-13; PMID:26518752; http://dx.doi.org/10.1016/j.bcp.2015.10.015
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tu MJ, Wang WP, Qiu JX, Yu AX, Yu AM. Genetically engineered miR-34a prodrug suppresses orthotopic osteosarcoma tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep 2016; 6:26611; PMID:27216562; http://dx.doi.org/10.1038/srep26611
   PubMed Web of Science ®Google Scholar